Intraocular drug delivery platform
Inventors
Sussman, Glenn Robert • Cable, II, Craig Alan • Kahook, Malik Y.
Assignees
University of Colorado Colorado Springs • Spyglass Pharma Inc
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12161548-B2
Publication Date
2024-12-10
Expiration Date
Abstract
An intraocular drug delivery platform including a ring having an anterior surface and a posterior surface opposite the anterior surface, a central aperture formed by the ring, a first haptic coupled to and extending outwards from the ring, a second haptic coupled to and extending outwards from the ring, a first drug eluting mass operably coupled to the anterior surface of the ring, and a second drug eluting mass operably coupled to the anterior surface of the ring and positioned directly opposite of the first drug eluting mass.
Core Innovation
The invention provides an intraocular implant with an intraocular drug delivery platform. The platform includes at least a partial ring having an anterior surface, a posterior surface opposite the anterior surface, and a central aperture formed by the ring, with at least one discrete compartment extending anteriorly from the anterior surface and integrated with the ring. A first drug eluting mass comprising a therapeutic agent is positioned in the first discrete compartment.
The intraocular drug delivery platform further includes a retention structure extending posteriorly from the posterior surface of the partial ring and at least partially circumscribing the central aperture. An intraocular lens (IOL) is configured to be retained in position by the retention structure, and the IOL includes an optic, a first lens haptic, and a second lens haptic. A posterior skirt circumscribes the aperture and defines a secondary aperture sized to retain and constrain the IOL.
The drug eluting masses are described as replaceable and integrated with the platform, with diffusion/elution control features described as semi-permeable membrane and/or perforations. Therapeutic agents described include bimatoprost, prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors, and rho kinase inhibitors, and matrices are described including silicone, hydrogel, and biodegradable polymer systems.
Claims Coverage
The provided independent claim coverage includes 2 inventive features. It recites a partial ring with a central aperture and an integrated discrete compartment holding a drug eluting mass, together with a posterior retention structure that retains an IOL.
Partial ring with central aperture and integrated anterior compartment
At least a partial ring comprising an anterior surface, a posterior surface opposite the anterior surface, and a central aperture formed by the ring; at least one discrete compartment extending anteriorly from the anterior surface of the ring and integrated with the ring; and a first drug eluting mass comprising a therapeutic agent positioned in the first discrete compartment.
Posterior retention structure circumscribing the central aperture to retain an IOL
A retention structure extending posteriorly from the posterior surface of the at least a partial ring and at least partially circumscribing the central aperture, wherein an intraocular lens (IOL) is configured to be retained in position by the retention structure of the intraocular drug delivery platform, the IOL comprising an optic, a first lens haptic, and a second lens haptic.
The independent claim covers an intraocular implant in which a partial ring with a central aperture supports an integrated anterior drug-eluting compartment, and a posterior retention structure circumscribes the aperture to retain an IOL including an optic and first and second lens haptics.
Stated Advantages
Limiting migration of the IOL toward the visual axis.
Allowing controlled movement of the IOL within the skirt/retention structure while retaining it in position.
Documented Applications
Placement/use in the capsular bag and/or the ciliary sulcus, including phakic, pseudophakic, and aphakic configurations.
Configurations where the platform (ring/skirt) itself carries the drug mass.
Interested in licensing this patent?